1. bookVolume 53 (2015): Issue 1 (March 2015)
Journal Details
License
Format
Journal
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
access type Open Access

IL-17, IL-6 and IFN-γ in systemic sclerosis patients

Published Online: 07 Oct 2015
Page range: 46 - 51
Received: 10 Feb 2015
Journal Details
License
Format
Journal
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
Abstract

Background. Systemic sclerosis (Ssc) is an autoimmune disease characterized by cutaneous and visceral fibrosis and its pathogenesis is incompletely understood. T helper cells are key regulators of the immune response and they seem to be involved in Ssc clinical manifestations. The aim of the study is to determine key cytokines secreted by Th1 (IFN-γ), Th2 (IL-6) and Th17 (IL-17) in Ssc patients and correlate them with specific manifestations of Ssc patients.

Material and methods. 35 consecutive Ssc patients and 20 age and sex matched controls were recruited. Serum IL-17, IFN-γ and IL-6 were determined using ELISA method.

Results. Serum IL-17 and IL-6 levels were not significantly different in Ssc patients and controls. Serum IFN-γ levels were higher in Ssc patients when compared to controls. Higher serum IFN-γ levels associated with pulmonary hypertension. After adjusting for gender and age, IL-17 levels remained independently associated with some clinical manifestations of Ssc patients (telangiectasia and high activity score of Ssc).

Conclusion. Th17 and Th1 cell responses are active in Ssc patients as their cytokines associated with higher disease activity scores and pulmonary manifestations. Th17 and Th1 specific activity and homing within Ssc patients still needs to be defined and determined in order to target them as potential future therapeutic targets in Ssc patients.

Keywords

1. BREMBILLA NC, CHIZZOLINI C. T cell abnormalities in systemic sclerosis with a focus on Th17 cells. Eur Cytokine Netw. 2012; 23(4):128-39.10.1684/ecn.2013.0325Search in Google Scholar

2. ZHU J, PAUL WE. CD4 T cells: fates, functions, and faults. Blood. 2008; 112(5):1557-69.10.1182/blood-2008-05-078154Search in Google Scholar

3. PAVLOVIC V, DIMIC A, MILENKOVIC S, KRTINIC D. Serum levels of IL-17, IL-4, and INFγ in Serbian patients with early rheumatoid arthritis. J Res Med Sci. 2014; 19(1):18-22.Search in Google Scholar

4. BĂLĂNESCU P, BĂLĂNESCU E, TĂNĂSESCU C, NICOLAU A, TĂNĂSESCU R, GRANCEA C, VAGU C, RUŢĂ S, BLEOŢU C. T helper 17 cell population in lupus erythematosus. Rom J Intern Med. 2010; 48(3):255-9.Search in Google Scholar

5. TANASESCU C, BALANESCU E, BALANESCU P, OLTEANU R, BADEA C, GRANCEA C, VAGU C, BLEOTU C, ARDELEANU C, GEORGESCU A. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med. 2010; 21(3):202-7.10.1016/j.ejim.2010.03.004Search in Google Scholar

6. CHIZZOLINI C, PAREL Y, SCHEJA A, DAYER JM. Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts. Arthritis Res Ther. 2006; 8(1):R10.10.1186/ar1860Search in Google Scholar

7. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.10.1002/art.1780230510Search in Google Scholar

8. GALIE N, HOEPER MM, HUMBERT M, TORBICKI A, VACHIERY JL, BARBERA JA, BEGHETTISearch in Google Scholar

9. M, CORRIS P, GAINE S, GIBBS JS, GOMEZ-SANCHEZ MA, JONDEAU G, KLEPETKO W, OPITZ C, PEACOCK A, RUBIN L, ZELLWEGER M, SIMONNEAU G, ESC Committee for Practice. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537.10.1093/eurheartj/ehp297Search in Google Scholar

10. CLEMENTS P , LACHENBRUCH P, SEIBOLD J, WHITE B, WEINER S, MARTIN R, WEINSTEIN A, WEISMAN M, MAYES M, COLLIER D. Inter- and intraobserver variability of the total thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22:1281-5.Search in Google Scholar

11. AMANZI L, BRASCHI F, FIORI G, GALLUCCIO F, MINIATI I, GUIDUCCI S, CONFORTI ML, KALOUDI O, NACCI F, SACU O, CANDELIERI A, PIGNONE A, RASERO L, CONFORTI D,MATUCCI-CERINIC M. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatolgy (Oxford) 2010; 49:1374-82.10.1093/rheumatology/keq097Search in Google Scholar

12. VALENTINI G, D’ANGELO S, DELLA ROSSA A, BENCIVELLI W, BOMBARDIERI S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis. 2003; 62(9):904-5.10.1136/ard.62.9.904Search in Google Scholar

13. OLEWICZ-GAWLIK A, DANCZAK-PAZDROWSKA A, KUZNAR-KAMINSKA B, GORNOWICZ-POROWSKA J, KATULSKA K, TRZYBULSKA D, BATURA-GABRYEL H, SILNY W, POPLAWSKI D, HRYCAJ P. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. Int J Rheum Dis. 2014; 17(6):664-70.10.1111/1756-185X.12290Search in Google Scholar

14. MURATA M, FUJIMOTO M, MATSUSHITA T, HAMAGUCHI Y, HASEGAWA M, TAKEHARA K, KOMURA K, SATO S. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci. 2008; 50(3):240-2.10.1016/j.jdermsci.2008.01.001Search in Google Scholar

15. ZHOU Y, HOU W, XU K, HAN D, JIANG C, MOU K, LI Y, MENG L, LU S. The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis. Hum Immunol. 2014 Dec 11. pii: S0198-8859(14)00508-4.Search in Google Scholar

16. GOURH P, ARNETT FC, ASSASSI S, TAN FK, HUANG M, DIEKMAN L, MAYES MD, REVEILLE JD, AGARWAL SK. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009; 11(5):R147.10.1186/ar2821Search in Google Scholar

17. RADSTAKE TR, VAN BON L, BROEN J, HUSSIANI A, HESSELSTRAND R, WUTTGE DM, DENG Y, SIMMS R, LUBBERTS E, LAFYATIS R. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One. 2009 Jun 17; 4(6):e5903.10.1371/journal.pone.0005903Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo